Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.
Pierre Brissot(Inserm), D. Alberti(Novartis (Switzerland)), J. Ford(University of Pisa), Franco Locatelli(Bambino Gesù Children's Hospital), Dominik Selleslag(National Institutes of Health), C. Ressayre-Djaffer(Novartis (Switzerland)), Alexis A. Thompson(Children's Hospital of Philadelphia), Bruno Turlin(Inserm), Adriana Berretta(Hospital Privado), Giovanni Quarta(Ospedale Papa Giovanni XXIII), B. Rabault(Novartis (Switzerland)), M. de Montalembert(Inserm), Giuliana Alimena
Cited by 10
Related Papers
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
|Clinical Infectious Diseases|2002|2.3k
A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload
|Journal of Biological Chemistry|2001|1.7k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738